National and Kapodistrian University of Athens
Ανίχνευση φορέων νοτιαίας μυϊκής ατροφίας με ποσοτικό PCR στο γενικό πληθυσμό
Abstract
dc:descriptionSpinal muscular atrophy (SMA) is one of the most common autosomalrecessive disorders worldwide: the carrier frequency is between 1/40 and 1/60in diverse populations and it affects 1 in 10 000 live births. SMA is caused bythe degeneration of anterior horn cells of the spinal cord, which leads tosymmetric proximal muscle weakness and atrophy. Based on the age at onsetand the clinical course, SMA is subdivided into three types: type I is aninfantile acute form and shows the greatest severity; type II is an infantilechronic form with intermediate severity and type III is a childhood andadolescent form and shows the mildest severity.All three types of SMA are linked mostly to the survival motor neuron (SMN)gene at 5q13, which is found as two nearly identical copies: SMN1 andSMN2. Mutations in the telomeric copy of the SMN gene (SMN1) areresponsible for SMA, whereas SMN2 functions as a disease-modifying genethat can ameliorate the clinical severity of SMA in a copy-dependent manner.Each SMN gene encompasses 27 kb and comprises of 9 exons (exons 1, 2a,2b, and 3–8). Typically, the DNA sequence of SMN1 differs from that of SMN2by only five nucleotides: One in intron 6, one in exon 7, two in intron 7, andone in exon 8. Of the SMA patients whose disorder is linked to 5q13, ∼96%are characterized by a homozygous deletion of SMN1 exon 7, which resultsfrom unequal crossover or SMN1-to-SMN2 conversion events. The remaining4% of cases are caused either by compound heterozygosity, with a point mutation in one allele and a deletion in the other, or by compoundheterozygous point mutations in the SMN1 gene.Given that homozygous deletion of exon 7 of SMN1 is a common genotypeand SMN2 can influence the severity of SMA, it is fundamentally important todirectly determine the copy numbers of SMN1 and SMN2 for carrier screeningand clinical/prenatal diagnosis of SMA. Using quantitative analysis ofSMN1/SMN2 gene dosage, a range of molecular investigations of theincidence of carriers and the genetic burden of SMA in diverse ethnicpopulations have been carried out. However, a population-based study ofSMA prevalence in Greece has not yet been executed. To estimate the futureburden of SMA and the requirements for its appropriate treatment,management and prevention in the Greek population, accurate populationfrequency data are essential. Such data could be obtained through thegenotyping of SMN genes in a large number of samples.In the study reported herein, we determined SMN copy number in 156 DNAsamples and from 44 core families with individuals with SMA, using Multiplexligation dependent probe amplification (MLPA), which has been proven to bea highly efficient and reliable carrier-screening test. The frequency of SMAcarriers in our population appears to be 1 in 52, which indicates that theprevalence of SMA among Greeks is the same as that among individuals inthe Western countries. We anticipate that our research will provide a basis fora nationwide program of clinical/prenatal diagnosis to prevent SMA in Greece.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Konstantinidis, Georgios
- Κωνσταντινίδης, Γεώργιος
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/41195